Paper39089293
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
McGowan BM and 9 others. Lancet Diabetes Endocrinol, 2024. Cited by 154 papers, by iCite.
Cite this record
ConductScience Library. Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Papers, record 39089293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39089293
- Disease
- obesity disorder354 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
- PubMed
- Publication types
- Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Research Support, Non-U.S. Gov't
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glucagon-Like Peptides | Major topic |
| Hypoglycemic Agents | Major topic |
| Obesity | Major topic |
| Prediabetic State | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Blood Glucose | |
| Double-Blind Method | |
| Treatment Outcome | |
| Weight Loss | |
| Semaglutide |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT05040971 | Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes | Results | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 39089292 | Prediabetes remission in people with obesity. | https://conductscience.org/library/papers/39089292 |
Source PubMed
Cited by105
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 154 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941232 | Weight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review. | Metabolites | 2026 | https://conductscience.org/library/papers/42941232 | PubMed |
| 42889937 | Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity. | Diabetes Obes Cardiometab CARE | 2026 | https://conductscience.org/library/papers/42889937 | PubMed |
| 42824923 | Predictors of treatment response to semaglutide for weight management. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42824923 | PubMed |
| 42789525 | Beyond Prescribing: GLP-1 Care and Obesity Prevention in Primary Care. | J Prim Care Community Health | 2026 | https://conductscience.org/library/papers/42789525 | PubMed |
| 42733128 | Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis. | Clin Obes | 2026 | https://conductscience.org/library/papers/42733128 | PubMed |
| 42718474 | Electroacupuncture enables semaglutide dose sparing in type 2 diabetes by boosting drug concentration and suppressing β-cell apoptosis. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42718474 | PubMed |
| 42673571 | Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis. | Endocrinol Diabetes Metab | 2026 | https://conductscience.org/library/papers/42673571 | PubMed |
| 42658458 | Prediabetes: diagnostic aspects, clinical features, and emerging therapeutic opportunities, with a focus on Vitamin D. | J Endocrinol Invest | 2026 | https://conductscience.org/library/papers/42658458 | PubMed |
| 42603240 | Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis. | Endocrine | 2026 | https://conductscience.org/library/papers/42603240 | PubMed |
| 42575984 | Type 2 diabetes prevention across the life course. | Nat Med | 2026 | https://conductscience.org/library/papers/42575984 | PubMed |
| 42560457 | Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis. | J Endocrinol Invest | 2026 | https://conductscience.org/library/papers/42560457 | PubMed |
| 42503575 | A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States. | Pharmacoeconomics | 2026 | https://conductscience.org/library/papers/42503575 | PubMed |
| 42482018 | Association of creatinine to body weight ratio with glycemic progression and remission in Chinese adults with prediabetes: a large-scale retrospective cohort study. | BMC Endocr Disord | 2026 | https://conductscience.org/library/papers/42482018 | PubMed |
| 42477297 | EndoBridge 2025: pearls and highlights. | Hormones (Athens) | 2026 | https://conductscience.org/library/papers/42477297 | PubMed |
| 42427356 | A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications. | Obes Sci Pract | 2026 | https://conductscience.org/library/papers/42427356 | PubMed |
| 42388883 | Beyond weight loss: predictors of treatment satisfaction and patient-reported outcomes in incretin-based therapies. A cross-sectional study. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42388883 | PubMed |
| 42381999 | Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition. | J Orthop Translat | 2026 | https://conductscience.org/library/papers/42381999 | PubMed |
| 42347027 | Proteomic Signatures of 3-Year Progression From Impaired Fasting Glucose to Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. | Diabetes Care | 2026 | https://conductscience.org/library/papers/42347027 | PubMed |
| 42316327 | Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis. | Diabetol Metab Syndr | 2026 | https://conductscience.org/library/papers/42316327 | PubMed |
| 42280424 | GLP-1RA- and Incretin-Based Therapies Within Lifestyle Interventions for Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. | Nutrients | 2026 | https://conductscience.org/library/papers/42280424 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GLP1R | 2740 | PubTator's text mining | https://conductscience.org/library/genes/2740 |
Source NCBI Gene
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| SEMAGLUTIDE | CHEMBL2108724 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL2108724 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39089293
GET https://conductscience.org/api/papers/v1/39089293/cited_by?page=2